

# Event Related Potentials as possible biomarker of ADHD symptoms severity in Tuberous Sclerosis complex (TSC)

***Dr. Stefano Pro***

*Neurophysiology Unit  
Bambino Gesù` Children's Hospital, IRCCS, Rome, Italy*





# Neurological and neuropsychiatric aspects of tuberous sclerosis complex

Paolo Curatolo, Romina Moavero, Petrus J de Vries



Lancet Neurol 2015; 14: 733-45

Tuberous sclerosis (also known as tuberous sclerosis complex [TSC]) is a multisystem genetic disorder that affects almost every organ in the body. Mutations in the *TSC1* or *TSC2* genes lead to disruption of the TSC1–TSC2 intracellular protein complex, causing overactivation of the mammalian target of rapamycin (mTOR) protein complex. The surveillance and management guidelines and clinical criteria for tuberous sclerosis were revised in 2012, and mTOR inhibitors are now recommended as treatment options for subependymal giant cell astrocytomas and renal angiomyolipomas—two common features of the disease. However, most morbidity and mortality caused by tuberous sclerosis is associated with neurological and neuropsychiatric manifestations. Treatment of epilepsy associated with tuberous sclerosis remains a major challenge, with more than 60% of patients having ongoing seizures. Tuberous-sclerosis-associated neuropsychiatric disorders (TAND) are multilevel and occur in most individuals with the disorder, but are rarely assessed and treated. Clinical trials of mTOR inhibitors to treat seizures and TAND are underway. Management of the neurological and neuropsychiatric manifestations of the disorder should be coordinated with treatment of other organ systems. In view of the age-related expression of manifestations from infancy to adulthood, continuity of clinical care and ongoing monitoring is paramount, and particular attention is needed to plan transition of patient care from childhood to adult services.

Neuroscience De Child Neurology Division, Univer: Tor Vergata, Ron (Prof P Curatolo & R Moavero MD); I Department, Chi Division, Bambin Children's Hospi Rome, Italy (R M Division of Child Adolescent Psyc University of Cap Cape Town, Sout (Prof P J de Vries I Correspondence 1

*Autosomal dominant multisystem disease characterized by hamartomas in several organs and systems*





Figure 4: TAND

TAND is used as an umbrella term to capture the range of neuropsychiatric disorders associated with tuberous sclerosis across different levels of investigation. TAND=tuberous-sclerosis-associated neuropsychiatric disorders.



# ADHD

## *Attention-Deficit Hyperactivity Disorder*

*General  
Population  
3-7%*



*TSC  
30-50%*



# Attention-Deficit Hyperactivity Disorder (ADHD) and Tuberous Sclerosis Complex

Journal of Child Neurology  
Volume 24 Number 10  
October 2009 1282-1287  
© 2009 The Author(s)  
10.1177/0883073809341272  
http://jcn.sagepub.com

Elisa D'Agati, MD, Romina Moavero, MD, Caterina Cerminara, MD, and Paolo Curatolo, MD

The neurobiological basis of attention-deficit hyperactivity disorder (ADHD) in tuberous sclerosis complex is still largely unknown. Cortical tubers may disrupt several brain networks that control different types of attention. Frontal lobe dysfunction due to seizures or epileptiform electroencephalographic discharges may perturb the development of brain systems that underpin attentional and hyperactive functions during a critical early stage of brain maturation. Comorbidity of attention-deficit hyperactivity disorder (ADHD) with mental retardation and autism spectrum disorders is frequent in children with tuberous sclerosis. Attention-deficit

hyperactivity disorder (ADHD) may also reflect a direct effect of the abnormal genetic program. Treatment of children with tuberous sclerosis complex with combined symptoms of attention-deficit hyperactivity disorder (ADHD) and epilepsy may represent a challenge for clinicians, because antiepileptic therapy and drugs used to treat attention-deficit hyperactivity disorder (ADHD) may aggravate the clinical picture of each other.

**Keywords:** ADHD; tuberous sclerosis complex; antiepileptic drugs; methylphenidate; autism

- >Cortical Tubers
- >Frontal Epileptiform abnormalities
- >Genetic mutation per se

Received: 6 May 2018 | Revised and accepted: 29 May 2018

DOI: 10.1002/ajmg.c.31637

WILEY AMERICAN JOURNAL OF medical genetics C  
Seminars in Medical Genetics

## RESEARCH REVIEW

# A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)

Petrus J. de Vries<sup>1</sup> | Lucy Wilde<sup>2</sup> | Magdalena C. de Vries<sup>1</sup> | Romina Moavero<sup>3,4</sup> | Deborah A. Pearson<sup>5</sup> | Paolo Curatolo<sup>3</sup>


<sup>1</sup>Division of Child and Adolescent Psychiatry, University of Cape Town, Cape Town, South Africa

<sup>2</sup>Cerebra Centre for Neurodevelopmental Disorders, School of Psychology, University of Birmingham, Birmingham, United Kingdom


<sup>3</sup>Child Neurology and Psychiatry Unit, Systems Medicine Department, University of Rome Tor Vergata, Rome, Italy

<sup>4</sup>Child Neurology Unit, Neuroscience and Neurorehabilitation Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

<sup>5</sup>Department of Psychiatry & Behavioral Sciences, McGovern Medical School, University of Texas Health Centre, Houston, Texas



**Figure 4: TAND**  
TAND is used as an umbrella term to capture the range of neuropsychiatric disorders associated with tuberous sclerosis across different levels of investigation. TAND=tuberous-sclerosis-associated neuropsychiatric disorders.






Brief description and generators

Auditory MMN	Discriminable change in auditory stimulation without attention; bilateral auditory-cortex with the contribution of right frontal cortex
P300	Sensitive (auditory/visual) measure of the capacity to allocate attentional resources; multiple cortical-subcortical, relatively independent generators


**GENERATORS of ERPs**



**Pre-  
Attentive**

**Attentive**





## MMN

>reflect an autonomic cerebral discrimination process not under attentive control

## P300

>reflect executive and attentional function

>may reflect late-stage monitoring of outcomes related to inhibitory process



# Auditory Event-Related Brain Potentials in Autistic Children and Three Different Control Groups

Chantal Kemner, Marinus N. Verbaten, Juliane M. Cuperus, Gert Camfferman, and Herman van Engeland

ERPs to auditory stimuli, generated during an oddball task, were obtained in a group of autistic children and three control groups (normal, ADHD, and dyslectic children, respectively). The task included the presentation of standards, deviants, and novels and had a (between-group) passive vs. active (counting) condition. It was examined whether 1) it was possible to replicate several earlier findings, 2) autistics manifest an abnormal lateralization pattern of ERPs, 3) autistics have an abnormal mismatch negativity (MMN), and 4) differences between autistics and normals are really specific to the autistic group. The only finding that could be replicated was that autistics have a smaller A/Pcz/300. There was no evidence for abnormal lateralization or abnormal MMN; however, there was an unexpected effect of the task manipulation on the amplitude of the P3: in autistics, the occipital P3 to deviant stimuli was significantly larger in the active than in the passive condition, a finding like the replication of the smaller A/Pcz/300.




Figure 5. The amplitude of the occipital P3 (averaged over O1, Oz, and O2) to deviant stimuli, in the passive as well as in the active condition, for each group separately (Groups × Task × Stimuli × AnPos effect). ADHD = attention deficit disorder with hyperactivity.

**MMN**  
 ↓/↑µV  
 ↑ms  
 ndr



## Original Paper

Neuropsychobiology

Neuropsychobiology 2016;73:131–138  
 DOI: 10.1159/000444490

Received: May 19, 2015  
 Accepted after revision: January 31, 2016  
 Published online: April 8, 2016

# Event-Related Potentials Correlate with the Severity of Child and Adolescent Patients with Attention Deficit/Hyperactivity Disorder

Kazuhiko Yamamuro<sup>a</sup> Toyosaku Ota<sup>a</sup> Junzo Iida<sup>b</sup> Yoko Nakanishi<sup>a</sup>  
 Yuko Suehiro<sup>a</sup> Hiroki Matsuura<sup>c</sup> Mitsuhiro Uratani<sup>d</sup> Kosuke Okazaki<sup>a</sup>  
 Naoko Kishimoto<sup>a</sup> Shohei Tanaka<sup>a</sup> Hidemi Iwasaka<sup>e</sup> Toshifumi Kishimoto<sup>a</sup>

<sup>a</sup>Department of Psychiatry and <sup>b</sup>Faculty of Nursing, Nara Medical University School of Medicine, Kashihara, <sup>c</sup>Department of Psychiatry, Tenri Hospital, Tenri, <sup>d</sup>Department of Psychiatry, Nara Prefectural General Rehabilitation Center, Shiki, and <sup>e</sup>Department of Education




Fig. 1. Representative P300 waveforms of child and adolescent patients with ADHD and controls. Black lines represent the ADHD group, and gray lines represent the control group, respectively. P300 amplitude is shown by arrows.

**!!!biomarker??**

**P300**  
 ↓µV  
 ↑ms






# Event-related potential components can be modified by ADHD pharmacotherapies

## Atomoxetine

### P300



## Methylphenidate

### MMN

> [Psychopharmacol Bull.](#) 1993;29(2):229-33.

### Mismatch negativity in hyperactive children: effects of methylphenidate

B G Winsberg<sup>1</sup>, D C Javitt, G S Silipo, P Doneshka

Affiliations + expand

PMID: 8290670

#### Abstract

This pilot study investigates electrophysiological correlates of methylphenidate (MP) treatment among hyperkinetic children who are clinical responders to therapy. Event-related potentials were obtained from a small sample (6 hyperactive and 5 controls) during an auditory "oddball" task. In the ignore condition, oddball tones elicited a frontocentral "mismatch" negativity (MMN) during the 100- to 200-msec latency range following stimulus presentation. In the attend condition, oddball target tones elicited a centroparietal P3 as well. MP significantly decreased hyperkinetic behaviors. Preliminary analyses of the electrophysiological data indicated a decreased amplitude of the P3 waveform among hyperkinetic children and a trend toward normalization on MP. Waveform abnormalities in the latency range of control MMN suggested either a decrease in MMN amplitude or an increase in MMN latency in hyperactive subjects along with a trend toward normalization by MP. The preliminary data are suggestive of information-processing abnormalities among hyperactive children that may be sensitive to MP therapy.



## ERPs as possible biomarker of ADHD symptoms severity in TSC ???

*The aim of this study was to investigate ERP characteristics in patients with ADHD secondary to TSC, compared to patients with drug-naive idiopathic ADHD and healthy controls (HCs), to investigate whether distinct clinical features can be due to different pathophysiological mechanisms.*

n°Pts			
13	idiopathic ADHD (iADHD)	4 females, 9 males	7 to 16 years (mean = 10.4 years, median = 9 years)
6	ADHD associated with TSC (tscADHD)	3 females, 6 males	8–15 years (mean = 12.6 years, median = 15 years)
14	age-matched healthy controls (HCs)	9 females, 5 males	8 to 16 years (mean = 11.9 years, median = 12.5 years)

*No difference in age was found between the groups of subjects (one-way ANOVA:  $F = 0.57$ ,  $P = 0.57$ )*



## Inclusion criteria

- > diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria and age 7–17 years.
- > iADHD patients did not have to present any other neurological or medical condition associated with ADHD.

## Exclusion criteria

- > intelligence quotient <70, psychiatric comorbidity, and sensory deficits
- > If ADHD was pharmacologically treated, children were asked to withdraw medications for 48 h before the neurophysiological and neuropsychological examination.


## *Clinical, EEG, neuroimaging characteristics of tscADHD pts*

Patient	Active epilepsy	AED treatment	IED	Brain MRI			
				Tubers	RML	SEN	SEGA
1	No	No	No	Yes, diffuse	Yes, diffuse	Yes	No
2	No	No	No	Yes, diffuse	Yes, diffuse	Yes	No
3	No	No	No	Yes, diffuse	Yes, diffuse	Yes	No
4	No	No	Yes, bilateral TO	Yes, diffuse	Yes, diffuse	Yes	No
5	No	No	No	Yes, diffuse	Yes, diffuse	Yes	No
6	No	CBZ	No	Yes, diffuse	Yes, diffuse	Yes	Yes

*\*Active epilepsy means epileptic seizures in the last 2 years. AED, antiepileptic drugs; IED, interictal epileptiform discharges; RML, radial migration lines; SEN, subependymal nodules; SEGA, subependymal giant cell astrocytomas; MRI, magnetic resonance imaging; CBZ, carbamazepine; TO, temporo-occipital.*




## Methods



### Cognitive and Neuropsychological Examination

All patients underwent the administration of an extensive battery of tests:

- Wechsler Intelligence Scale for Children for the determination of the IQ
- Tower of London test for the assessment of planning and problem solving skills and cognitive flexibility
- span of forward and backward memory numbers (DSF and DSB) for the measurement of short-term verbal memory and working memory
- Trail-Making Test Part A and Part B for the evaluation of visual search strategies, selective and divided attention
- phonological (FAS) and semantic (CAT) verbal fluency test for the evaluation of verbal ability to access vocabulary by phonological and semantic means
- Subtest ToM and ER of the NEPSY-II battery to assess the ability to recognize one's own and others' mental states and the ability to recognize facial expressions
- Physical and Neurological Assessment of Subtle Signs to evaluate minor neurological signs
- Schedule for Affective Disorders and Schizophrenia for School-Aged Children—Present and Lifetime Version, a psychodiagnostic tool for the assessment of psychopathological symptoms in children and adolescents according to DSM-IV Text Revision criteria
- Conners' Parents and Teachers Rating Scale—Revised, questionnaires to be filled in by parents and/or teachers, used for the evaluation of ADHD from 3 to 17 years, and for externalizing disorders that can be found in comorbidities; they also provide an index (ADHD Index), which is able to differentiate subjects affected by unaffected
- Child Behavior Checklist for Ages 6–18, questionnaire to be filled in by parents, which assesses the presence of internalizing and externalizing symptoms in children and adolescents aged between 6 and 18 years.





# MMN

## Literature data

### iADHD:

↓/↑μV

↑ms

ndr

## Our data

### i/tscADHD:

↑μV

↓ms



Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

SCIENCE @ DIRECT®

Cognitive Brain Research 25 (2005) 891–899

COGNITIVE  
BRAIN  
RESEARCH

[www.elsevier.com/locate/cogbr](http://www.elsevier.com/locate/cogbr)



Research Report

Attentional load of the primary task influences the frontal but not the temporal generators of mismatch negativity

Domenico Restuccia<sup>a,b,\*</sup>, Giacomo Della Marca<sup>a</sup>, Camillo Marra<sup>a</sup>,  
Marco Rubino<sup>a</sup>, Massimiliano Valeriani<sup>c</sup>


<sup>a</sup>Department of Neurosciences, Catholic University, Policlinico A. Gemelli, L.go A. Gemelli 8, 00168 Rome, Italy  
<sup>b</sup>Scientific Institute "E. Medea"—Regional Scientific Research Center of San Vito al Tagliamento and Pavia di Prato, Italy  
<sup>c</sup>Division of Neurology, Pediatric Hospital "Bambino Gesù", IRCCS, Rome, Italy

## MMN



Concomitant highly demanding task  
→ Bilateral Auditory cortex + **Frontal source ?**








Mean values of total (TIQ), verbal (VIQ), and performance (PIQ) intelligent quotient in patients with idiopathic ADHD compared to patients to ADHD associated with TSC.

	iADHD	tscADHD	<i>P</i>
TIQ	105.9	85.8	0.004
VIQ	113.9	92.2	0.016
PIQ	109.1	91.3	0.032

Total IQ



P300 amplitude




## P300 $\mu\text{V}$ iADHD < HCs

- Reduced attention orienting to warning stimuli
- Failure to allocate sufficient attentional resources to stimulus evaluation process due to reduced attentional capacity

## P300 $\mu\text{V}$ tscADHD $\approx$ HCs ???


P300 amplitude might be influenced by different variables, especially by **cognitive factors**



Mean values of the results obtained in neuropsychological tests administered in subjects with idiopathic ADHD and ADHD with TSC.

	iADHD	tscADHD	<i>P</i>
ToL (z)	-0.7	-1.22	0.08
DSF	-0.43	-2.15	<b>0.006</b>
DSB	-0.05	-1.22	0.05
FAS	-1.2	-1.24	0.87
CAT	-1.7	-3.51	<b>0.018</b>
TMTA (s)	62.4	81.33	0.47
TMTB (s)	148.3	114	0.32
CPRS- opp	60.76	66.83	0.43
CPRS-inatt	74.61	80.33	0.5
CPRS-hyper	68.53	70.16	0.83
CPRS-ADHD index	76.61	78.66	0.75

Significant *P* values in bold. ToL, Tower of London; DSF, direct number span; DSB, span of inverse numbers; FAS, phonemic fluency; CAT, categorical fluency; CAT TMTA, Trail-Making Test Part A; TMTB, Trail-Making Test Part B.





**Marked Network  
dysregulation in TSC**



***P300 amplitude does not really reflect  
symptom severity in TSC***

**Cortical Tubers  
Frontal Epileptiform abnormalities  
Genetic mutation *per se***

Patient	Active epilepsy	AED treatment	IED	Brain MRI			
				Tubers	RML	SEN	SEGA
1	No	No	No	Yes, diffuse	Yes, diffuse	Yes	No
2	No	No	No	Yes, diffuse	Yes, diffuse	Yes	No
3	No	No	No	Yes, diffuse	Yes, diffuse	Yes	No
4	No	No	Yes, bilateral TO	Yes, diffuse	Yes, diffuse	Yes	No
5	No	No	No	Yes, diffuse	Yes, diffuse	Yes	No
6	No	CBZ	No	Yes, diffuse	Yes, diffuse	Yes	Yes

\*Active epilepsy means epileptic seizures in the last 2 years. AED, antiepileptic drugs; IED, interictal epileptiform discharges; RML, radial migration lines; SEN, subependymal nodules; SEGA, subependymal giant cell astrocytomas; MRI, magnetic resonance imaging; CBZ, carbamazepine; TO, temporo-occipital.




**$I = tsc$**   
**ADHD  
phenotype**

**Pre-Attentive  
process**


**Attentive  
process**

**$I \neq tsc$**   
**ADHD  
etiology**






*Thanks*

 **frontiers**  
in Neurology

ORIGINAL RESEARCH  
published: 10 July 2020  
doi: 10.3389/fneur.2020.00646



**Event-Related Potentials in ADHD Associated With Tuberous Sclerosis Complex: A Possible Biomarker of Symptoms Severity?**

**Romina Moavero<sup>1,2\*</sup>, Sara Marciano<sup>1</sup>, Stefano Pro<sup>2</sup>, Donata De Stefano<sup>2</sup>, Federico Vigeveno<sup>2</sup>, Paolo Curatolo<sup>1</sup> and Massimiliano Valeriani<sup>2,3</sup>**

OPEN ACCESS

**Edited by:**  
Marco Carotenuto,  
University of Campania Luigi  
Vanvitelli, Italy

<sup>1</sup> Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University of Rome, Rome, Italy; <sup>2</sup> Child Neurology Unit, Neuroscience and Neurorehabilitation Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; <sup>3</sup> Center for Sensory Motor Interaction Aalborg University, Aalborg, Denmark